Grants and Contributions:
Title:
Lead optimization of anti-cancer agents
Agreement Number:
980818
Agreement Value:
$56,803.00
Agreement Date:
Oct 11, 2021 - Jun 30, 2022
Description:
Lead optimization of a novel class of small molecule anti-cancer agents through evaluation of their pharmacokinetic profiles and ability to penetrate the blood brain barrier.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6B 0A5
Reference Number:
172-2021-2022-Q3-980818
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
795712470
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 107 days.
Amendment Date
Mar 1, 2022
Recipient's Legal Name:
Rakovina Therapeutics Inc.
Federal Riding Name:
Vancouver Centre
Federal Riding Number:
59034
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: